Non-bacterial thrombotic endocarditis epidemiology and demographics
|
non-bacterial thrombotic endocarditis |
|
Differentiating non-bacterial thrombotic endocarditis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Non-bacterial thrombotic endocarditis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Non-bacterial thrombotic endocarditis epidemiology and demographics |
|
FDA on Non-bacterial thrombotic endocarditis epidemiology and demographics |
|
CDC on Non-bacterial thrombotic endocarditis epidemiology and demographics |
|
Non-bacterial thrombotic endocarditis epidemiology and demographics in the news |
|
Blogs on Non-bacterial thrombotic endocarditis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]
Overview
Non-bacterial thrombotic endocarditis is a rare autopsy finding. Although the exact incidence of NBTE is unknown, it is thought to be approximately 900-600 per 100,000 individuals worldwide. The prevalence of NBTE is approximately 9,300 per 100,000 individuals worldwide. Patients of all age groups may develop NBTE, usually in the 4th to 8th decade. There is no racial predilection to NBTE, and NBTE affects men and women equally.
Epidemiology and Demographics
Incidence
- Non-bacterial thrombotic endocarditis is a rare autopsy finding[1].
- It is a rare disease that tends to affect patients with advanced malignancies[2][3] and patients with autoimmune disorders[4].
- Although the exact incidence of NBTE is unknown, it is thought to be approximately 900-600 per 100,000 individuals worldwide[5][6].
Prevalence
- The prevalence of NBTE is approximately 9,300 per 100,000 individuals worldwide[7].
Age
- Patients of all age groups may develop NBTE[8].
- NBTE commonly affects individuals between the ages of 40-80years of age[7][9].
Race
- There is no racial predilection to NBTE[8].
Gender
References
- ↑ Llenas-García J, Guerra-Vales JM, Montes-Moreno S, López-Ríos F, Castelbón-Fernández FJ, Chimeno-García J (May 2007). "[Nonbacterial thrombotic endocarditis: clinicopathologic study of a necropsy series]". Rev Esp Cardiol (in Spanish; Castilian). 60 (5): 493–500. PMID 17535760.
- ↑ Edoute Y, Haim N, Rinkevich D, Brenner B, Reisner SA (March 1997). "Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients". Am. J. Med. 102 (3): 252–8. doi:10.1016/S0002-9343(96)00457-3. PMID 9217593.
- ↑ Kalangos A, Pretre R, Girardet C, Ricou E, Faidutti B (February 1997). "An atypical aortic valve non-bacterial thrombotic endocarditis in the course of multiple myeloma". Eur. Heart J. 18 (2): 351–2. doi:10.1093/oxfordjournals.eurheartj.a015243. PMID 9043857.
- ↑ Hojnik M, George J, Ziporen L, Shoenfeld Y (April 1996). "Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome". Circulation. 93 (8): 1579–87. doi:10.1161/01.cir.93.8.1579. PMID 8608627.
- ↑ Deppisch LM, Fayemi AO (December 1976). "Non-bacterial thrombotic endocarditis: clinicopathologic correlations". Am. Heart J. 92 (6): 723–9. doi:10.1016/s0002-8703(76)80008-7. PMID 998478.
- ↑ González Quintela A, Candela MJ, Vidal C, Román J, Aramburo P (1991). "Non-bacterial thrombotic endocarditis in cancer patients". Acta Cardiol. 46 (1): 1–9. PMID 1851590.
- ↑ 7.0 7.1 7.2 Kuramoto K, Matsushita S, Yamanouchi H (September 1984). "Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction". Jpn. Circ. J. 48 (9): 1000–6. doi:10.1253/jcj.48.1000. PMID 6481938.
- ↑ 8.0 8.1 8.2 Lopez JA, Ross RS, Fishbein MC, Siegel RJ (March 1987). "Nonbacterial thrombotic endocarditis: a review". Am. Heart J. 113 (3): 773–84. doi:10.1016/0002-8703(87)90719-8. PMID 3548296.
- ↑ ANGRIST A, MARQUISS J (1954). "The changing morphologic picture of endocarditis since the advent of chemotherapy and antibiotic agents". Am. J. Pathol. 30 (1): 39–63. PMC 1942455. PMID 13124459.